COPD: A step-care approach when FEV1 is deteriorating

Research output: Contribution to journalArticle

Abstract

Early recognition of chronic obstructive pulmonary disease is particularly important because treatment of severe disease is often unsatisfactory and survival is strongly related to forced expiratory volume in 1 second (FEV1) at the time of diagnosis. Smoking cessation is one of the few interventions that has been demonstrated to reduce the rate of decline in lung function. Ipratropium is the initial drag of choice, but patients may require as many as 24 to 32 puffs a day. β2-Adrenergic agonists are also useful, although the optimum dosages have not yet been established. For selected patients, theophylline offers several benefits, including enhanced mucociliary clearance as well as bronchodilation. Inhaled corticosteroids may be a useful addition to ipratropium or β2-adrenergic agonists, since they can improve FEV1 and reduce bronchial hyperresponsiveness. Oral corticosteroids are not routinely recommended, but a 3- to 4-week trial of prednisone may be useful for managing acute exacerbations. Iodinated glycerol or supersaturated potassium iodide may benefit patients with excessive or thick mucus production. Continuous oxygen therapy is indicated for patients who have an oxygen saturation below 90% despite appropriate pharmacologic therapy.

Original languageEnglish (US)
Pages (from-to)1673-1687
Number of pages15
JournalConsultant
Volume37
Issue number6
StatePublished - Jun 1997

Fingerprint

Forced Expiratory Volume
Chronic Obstructive Pulmonary Disease
Ipratropium
Adrenergic Agonists
Adrenal Cortex Hormones
Oxygen
Mucociliary Clearance
Potassium Iodide
Smoking Cessation
Mucus
Theophylline
Prednisone
Therapeutics
Lung
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

COPD : A step-care approach when FEV1 is deteriorating. / Boyars, Michael.

In: Consultant, Vol. 37, No. 6, 06.1997, p. 1673-1687.

Research output: Contribution to journalArticle

@article{2562844d32e24fa7a29d7db464f587d1,
title = "COPD: A step-care approach when FEV1 is deteriorating",
abstract = "Early recognition of chronic obstructive pulmonary disease is particularly important because treatment of severe disease is often unsatisfactory and survival is strongly related to forced expiratory volume in 1 second (FEV1) at the time of diagnosis. Smoking cessation is one of the few interventions that has been demonstrated to reduce the rate of decline in lung function. Ipratropium is the initial drag of choice, but patients may require as many as 24 to 32 puffs a day. β2-Adrenergic agonists are also useful, although the optimum dosages have not yet been established. For selected patients, theophylline offers several benefits, including enhanced mucociliary clearance as well as bronchodilation. Inhaled corticosteroids may be a useful addition to ipratropium or β2-adrenergic agonists, since they can improve FEV1 and reduce bronchial hyperresponsiveness. Oral corticosteroids are not routinely recommended, but a 3- to 4-week trial of prednisone may be useful for managing acute exacerbations. Iodinated glycerol or supersaturated potassium iodide may benefit patients with excessive or thick mucus production. Continuous oxygen therapy is indicated for patients who have an oxygen saturation below 90{\%} despite appropriate pharmacologic therapy.",
author = "Michael Boyars",
year = "1997",
month = "6",
language = "English (US)",
volume = "37",
pages = "1673--1687",
journal = "Consultant",
issn = "0010-7069",
publisher = "Cliggott Publishing Co.",
number = "6",

}

TY - JOUR

T1 - COPD

T2 - A step-care approach when FEV1 is deteriorating

AU - Boyars, Michael

PY - 1997/6

Y1 - 1997/6

N2 - Early recognition of chronic obstructive pulmonary disease is particularly important because treatment of severe disease is often unsatisfactory and survival is strongly related to forced expiratory volume in 1 second (FEV1) at the time of diagnosis. Smoking cessation is one of the few interventions that has been demonstrated to reduce the rate of decline in lung function. Ipratropium is the initial drag of choice, but patients may require as many as 24 to 32 puffs a day. β2-Adrenergic agonists are also useful, although the optimum dosages have not yet been established. For selected patients, theophylline offers several benefits, including enhanced mucociliary clearance as well as bronchodilation. Inhaled corticosteroids may be a useful addition to ipratropium or β2-adrenergic agonists, since they can improve FEV1 and reduce bronchial hyperresponsiveness. Oral corticosteroids are not routinely recommended, but a 3- to 4-week trial of prednisone may be useful for managing acute exacerbations. Iodinated glycerol or supersaturated potassium iodide may benefit patients with excessive or thick mucus production. Continuous oxygen therapy is indicated for patients who have an oxygen saturation below 90% despite appropriate pharmacologic therapy.

AB - Early recognition of chronic obstructive pulmonary disease is particularly important because treatment of severe disease is often unsatisfactory and survival is strongly related to forced expiratory volume in 1 second (FEV1) at the time of diagnosis. Smoking cessation is one of the few interventions that has been demonstrated to reduce the rate of decline in lung function. Ipratropium is the initial drag of choice, but patients may require as many as 24 to 32 puffs a day. β2-Adrenergic agonists are also useful, although the optimum dosages have not yet been established. For selected patients, theophylline offers several benefits, including enhanced mucociliary clearance as well as bronchodilation. Inhaled corticosteroids may be a useful addition to ipratropium or β2-adrenergic agonists, since they can improve FEV1 and reduce bronchial hyperresponsiveness. Oral corticosteroids are not routinely recommended, but a 3- to 4-week trial of prednisone may be useful for managing acute exacerbations. Iodinated glycerol or supersaturated potassium iodide may benefit patients with excessive or thick mucus production. Continuous oxygen therapy is indicated for patients who have an oxygen saturation below 90% despite appropriate pharmacologic therapy.

UR - http://www.scopus.com/inward/record.url?scp=0031296099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031296099&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031296099

VL - 37

SP - 1673

EP - 1687

JO - Consultant

JF - Consultant

SN - 0010-7069

IS - 6

ER -